Abzena provides a suite of complementary services and technologies to R&D organisations to improve the chances of successful development and manufacture of therapeutic proteins and antibodies, and it is therefore poised to capitalise on the growth of the biopharmaceutical market. The Group has significant know-how, supported by a broad patent estate, to enable it to create better biopharmaceuticals for its partners.Abzena operates a balanced business model with growing revenues from its service business and the potential for significant future growth through royalty bearing licences for the application of its technologies to biopharmaceutical products. Abzena has been developing and offering their technologies and services for over 10 years and their scientists have provided expertise to a wide range of companies, including most of the top 20 biopharmaceutical companies, many large and small public and private biotech, and academic groups, across the world.

• Kept a track record of contributions to projects across therapeutic areas, such as CNS, cardiovascular, diabetes, obesity, anti-viral, and anti-infectious diseases.• As the key contributor, starting from combinatorial synthesis, designed, developed, synthesized and delivered a Pre-Clinical Candidate (PCC) as a HIV protease inhibitor for the treatment of PI-resistant viral strains.• Contributed to the development of a CETP (cholesteryl ester transfer protein) inhibitor for phase III clinical study (on-going).• As a major contributor, designed and synthesized several lead compounds, in several different structure series, for the Human Glucagon Receptor Antagonist project. Developed a spiro-urea compound for this project as the bench-mark, which is used inside and outside the company.• Designed and synthesized a novel water soluble thiazolyl cyclic peptide as antibiotic.• As a major contributor, designed and synthesized benzoylnaphthylacetanides as potassium channel blockers for the treatment of ocular hypertension.• Designed and synthesized several bench-mark compounds as Thrombin Receptor Antagonists (TRA) for the treatment of cardiovascular disease.• Contributed to the development of M4 activator project, for the treatment of Alzheimer’s disease.• Contributed to the development of LRRK2 project, for the treatment of Parkinson’s disease.• Designed and developed efficient synthetic methods for three major projects.• Coordinated cross function activities for the Lead Optimization of TRA project.• Coordinated cross function, cross sites, and internal-external sample management for the LRRK2 project.

Contributed to the discovery of novel α1a Adrenoceptor-Selective Antagonists for the treatment of human benign prostatic hyperplasia (BPH).